Van professionele vertalers, bedrijven, webpagina's en gratis beschikbare vertaalbronnen.
na podlagi populacijske farmakokinetične analize podatkov iz študij 1001, 1005 in 1007 telesna masa in spol nimata klinično pomembnega vpliva na farmakokinetiko krizotiniba.
based on the population pharmacokinetic analysis of data from studies 1001, 1005 and 1007, there was no clinically meaningful effect of body weight or gender on crizotinib pharmacokinetics.
noben bolnik v skupini s krizotinibom v randomiziranih študijah 3. faze, Študiji 1007 in 1014, ter enoskupinski Študiji 1005 ni bil star 85 let.
no patients in the crizotinib arm of randomised phase 3 studies 1007 and 1014, and single arm study 1005 were >85 years.
podatki o učinkovitosti iz Študije 1007 so povzeti v preglednici 5, kaplan-meierjevi krivulji za pfs in os pa sta prikazani na slikah 3 oziroma 4.
efficacy data from study 1007 are summarised in table 5, and the kaplan-meier curves for pfs and os are shown in figure 3 and 4, respectively.